Related Experiment Video
Updated: Sep 6, 2025
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Evaluating the Effects of Separate and Concomitant Use of MK-2206 and Salinomycin on Prostate Cancer Cell Line
Mohamadreza Savaee1, Ali Bakhshi1, Fatemeh Yaghoubi1
1Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
Background:
Prostate cancer is known as one of the most prevalent health disorders in the male population globally. The aim of the current study was to evaluate the effects of separate and concomitant use of MK-2206 and salinomycin on prostate cancer cell line.
Methods:
The antitumor potential of separate and concomitant use of MK-2206 and salinomycin was evaluated in a panel of prostate cancer cell line (PC-3). To get insights into the underlying mechanism of action, different assays including the rate of apoptosis, cell viability, and gene expression were performed in treated prostate cancer cells.
Results:
A significant reduction was detected in the viability percentage of prostate cancer cells (p< 0.001) and the rate of Akt expression (p< 0.001) in all salinomycin, MK-2206, and salinomycin+MK-2206 groups compared to the negative control group. Furthermore, in comparison with the negative control group, there was a notable increase in both the rate of Bad expression (p< 0.001) and prostate cancer cells apoptosis after salinomycin, MK-2206, and salinomycin+MK-2206 treatments. Moreover, the concomitant use of salinomycin+MK-2206 revealed synergistic improvements regarding the viability of prostate cancer cells and the rate of the Akt and Bad expressions compared to the separate administration of salinomycin and MK-2206 (all p< 0.05).
Conclusion:
The findings of the present study may contribute to improving the efficacy of the therapies regarding the management of prostate cancer and providing a beneficial strategy in clinical trials.
Insights
This study investigated MK-2206 and salinomycin for prostate cancer treatment. Their combined use synergistically reduced cancer cell viability and modulated key protein expressions, offering a promising therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Prostate cancer is a globally prevalent health concern in males.
- Current therapeutic strategies require optimization for improved efficacy.
Purpose of the Study:
- To evaluate the individual and combined effects of MK-2206 and salinomycin on prostate cancer cells.
- To elucidate the underlying mechanisms of action, including apoptosis and gene expression changes.
Main Methods:
- Utilized a prostate cancer cell line (PC-3) for in vitro experiments.
- Assessed cell viability, apoptosis rates, and gene expression (Akt, Bad) following drug treatments.
Main Results:
- Both MK-2206 and salinomycin significantly reduced prostate cancer cell viability and increased apoptosis.
- Combined treatment demonstrated synergistic effects, enhancing the reduction in cell viability and modulating Akt and Bad expression more effectively than individual treatments.
- Significant changes in Akt and Bad expression were observed across all treatment groups compared to controls.
Conclusions:
- The combination of MK-2206 and salinomycin shows synergistic potential for prostate cancer therapy.
- These findings support the development of this combination as a beneficial strategy for clinical trials in prostate cancer management.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
